• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/15/25 8:05:13 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    false 0001574235 0001574235 2025-05-15 2025-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 15, 2025

     

    PULMATRIX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36199   46-1821392

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    945 Concord Street, Suite 1217

    Framingham, MA 01701

    (Address of principal executive offices) (Zip Code)

     

    (888) 355-4440

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 15, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    99.1   Press Release dated May 15, 2025*
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

    * This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PULMATRIX, INC.
         
    Date: May 15, 2025 By: /s/ Peter Ludlum
        Peter Ludlum
        Interim Chief Executive Officer and Interim Chief Financial Officer

     

     

     

    Get the next $PULM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    SEC Filings

    See more
    • SEC Form 425 filed by Pulmatrix Inc.

      425 - Pulmatrix, Inc. (0001574235) (Subject)

      6/16/25 4:17:07 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix Inc. filed SEC Form 8-K: Other Events

      8-K - Pulmatrix, Inc. (0001574235) (Filer)

      6/16/25 4:15:38 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pulmatrix Inc.

      10-Q - Pulmatrix, Inc. (0001574235) (Filer)

      5/15/25 8:20:43 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care